Alembic Pharmaceuticals Limited Stock price

Equities

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
984.8 INR +0.01% Intraday chart for Alembic Pharmaceuticals Limited +2.05% +29.68%
Sales 2024 * 63.38B 761M Sales 2025 * 70.38B 845M Capitalization 194B 2.32B
Net income 2024 * 5.95B 71.41M Net income 2025 * 7.03B 84.34M EV / Sales 2024 * 3.1 x
Net Debt 2024 * 2.62B 31.4M Net cash position 2025 * 457M 5.49M EV / Sales 2025 * 2.74 x
P/E ratio 2024 *
32.6 x
P/E ratio 2025 *
27.6 x
Employees 14,593
Yield 2024 *
0.9%
Yield 2025 *
1.02%
Free-Float 29.28%
More Fundamentals * Assessed data
Dynamic Chart
Alembic Pharmaceuticals Limited Receives Order from Commission of Customs, Mumbai Zone- III CI
Alembic Pharmaceuticals' Oncology Plant in Gujarat, India Gets One Observation from US FDA MT
Alembic Pharmaceuticals Limited Announces United States Food and Drug Administration Conducted an Inspection At Oncology Formulation Facility At Panelav CI
Crisil Keeps AA+ Rating on Alembic Pharmaceuticals' Bank Loans with Stable Outlook MT
Indian shares seen muted tracking broader Asian equities RE
Alembic Pharmaceuticals Fully Resumes Operations at Manufacturing Unit in South Sikkim, India MT
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q3; EPS Tops Estimates MT
Alembic Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q3, EPS Beats Estimates MT
Transcript : Alembic Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Alembic Pharmaceuticals Limited Announces Designation of Manuj Desai as Head - It as Senior Management Personnel CI
Alembic Pharmaceuticals Expects Operations at Sikkim, India Units to Be Restores in Two Months MT
Alembic Pharmaceuticals Extends Corporate Guarantee to US-Based Arm to Secure Credit MT
Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals CI
More news

Latest transcript on Alembic Pharmaceuticals Limited

1 day+0.01%
1 week+2.05%
Current month-3.42%
1 month-4.27%
3 months+30.39%
6 months+29.09%
Current year+29.68%
More quotes
1 week
947.30
Extreme 947.3
997.35
1 month
901.80
Extreme 901.8
1 080.00
Current year
773.40
Extreme 773.4
1 094.00
1 year
462.30
Extreme 462.3
1 094.00
3 years
462.30
Extreme 462.3
1 094.00
5 years
434.80
Extreme 434.8
1 145.00
10 years
227.00
Extreme 227
1 145.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 76 83-04-30
Director of Finance/CFO 64 03-01-17
Compliance Officer - 23-03-31
Members of the board TitleAgeSince
Chief Executive Officer 76 83-04-30
Director of Finance/CFO 64 03-01-17
Director/Board Member 56 15-02-03
More insiders
Date Price Change Volume
24-03-28 984.8 +0.01% 141 639
24-03-27 984.8 +1.78% 134,979
24-03-26 967.5 +1.05% 58,691
24-03-22 957.4 -0.79% 51,337
24-03-21 965 +2.07% 209,400

Delayed Quote NSE India S.E., March 28, 2024 at 08:01 am EDT

More quotes
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
984.8 INR
Average target price
901.1 INR
Spread / Average Target
-8.50%
Consensus
  1. Stock
  2. Equities
  3. Stock Alembic Pharmaceuticals Limited - NSE India S.E.